Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical)

重组抗CD38和CD3双特异性抗体

Report date: 2026/03/19 17:23:39

Base Information

Drug NameY-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical)
Drug Alias NameY-150Y150
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT lymphocytes stimulantsAnti-CD38Anti-CD3
TargetsLymphocyte differentiation antigen CD38T cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Yzy Biopharma Co LtdCSPC Pharmaceutical Group Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan Yzy Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A